VYGR

#3570
Voyager Therapeutics, Inc. - Common Stock
3.5 4 USD
+0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.54
3.54
Jahresspanne
2.94
5.48
Tagesänderung
+2.31%
Monatliche Änderung
+13.46%
6 month change
-12.38%
Jahresänderung
-23.87%
Vorheriger Schlusskurs
3.4 6
Open
3.5 4
Tief
3.5 4
Hoch
3.5 4
Volumen
38
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Voyager Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Voyager Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Voyager Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Voyager Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Voyager Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Voyager Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Voyager Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Voyager Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Voyager Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Voyager Therapeutics, Inc. current report, Q1 FY2026
8-K

Voyager Therapeutics, Inc. current report, Q2 FY2024

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Voyager Therapeutics, Inc. (VYGR) on June 13, 2024, regarding events occurring on June 11, 2024. The filing discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.

Material Changes

The primary material change is the appointment of Nathan Jorgensen, Ph.D., M.B.A., as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer. His employment is scheduled to commence no later than July 8, 2024. Robin Swartz will continue to serve as Chief Operating Officer.

Guidance, Outlook, and Compensation Details

The filing details the compensation package for Dr. Jorgensen, which includes:

  • Base Salary: $480,000 annually.
  • Cash Bonus: Target level of 40% of the annual base salary, payable at the Board's discretion.
  • Equity Awards:
    • Stock option to purchase 200,000 shares, vesting over four years (25% on the first anniversary, remaining 75% monthly).
    • Restricted Stock Unit (RSU) award for 80,000 shares, vesting over three years (33.333% annually).
  • Severance: In the event of termination without "cause" or resignation for "good reason," Dr. Jorgensen is eligible for 12 months of base salary continuation, a pro rata bonus, and COBRA coverage. If termination occurs within 12 months of a "sale event," full acceleration of service-based equity vesting applies.

The equity awards were granted outside the Company's 2015 Stock Option and Incentive Plan as an inducement material to employment under Nasdaq Listing Rule 5635(c)(4).

Investor Verification Checklist

  • Verify the commencement date of Dr. Jorgensen's employment (no later than July 8, 2024).
  • Review the attached Exhibit 10.1 for the full text of the employment agreement and specific definitions of "cause," "good reason," and "sale event."
  • Confirm the exercise price of the stock options, which is tied to the closing share price on the commencement date.
  • Monitor future filings for any changes to the Company's financial leadership or capital structure resulting from this appointment.

Nachrichten